Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is 3.21 as of 2026-10-06T22:32:53.217Z.
Calculation as of: 2026-10-06T22:32:53.217Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66afd7ad6fe085f612ae866be6517f9e897c4fba6e73e474a8e5d595bf17d99d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
3.21
SECTOR MEDIAN · HEALTHCARE
2.39
median of 761 covered companies
CURRENT VS SECTOR MEDIAN
+34.31%
vs the sector median at left
Market Cap
$3.52B
PB Ratio
18.94
TTM Avg
32.44
3Y Avg
31.98
5Y Avg
24.76
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.36B | 3.21 | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 2.59 | 3.81 | 5.55 | 6.29 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 8.11 | 6.81 | 6.62 | 5.49 |
| CareDx, Inc (CDNA)vs › | $3.30B | 7.75 | 4.07 | 3.37 | 3.09 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 34.60 | 20.51 | 16.51 | 13.32 |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | 63.22 | 23.87 | 15.64 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | 2.91 | 2.88 | 2.93 | 2.66 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | 18.94 | 32.44 | 31.98 | 24.76 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | 2.85 | 5.42 | 4.34 | 4.03 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 9.20 | 8.74 | 6.54 | 4.84 |
P/B Ratio
3.21
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
